Mangoceuticals, Total Debt To Capitalization from 2010 to 2024

MGRX Stock   2.53  0.05  2.02%   
Mangoceuticals, Common Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization will likely drop to 0.07 in 2024. During the period from 2010 to 2024, Mangoceuticals, Common Total Debt To Capitalization regression line of annual values had r-squared of  0.49 and arithmetic mean of  1.42. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.075993
Current Value
0.0722
Quarterly Volatility
0.67170526
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.4 K, Interest Expense of 0.0 or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 7.7, Dividend Yield of 0.0 or PTB Ratio of 8.03. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
  
Check out the analysis of Mangoceuticals, Common Correlation against competitors.

Latest Mangoceuticals, Common's Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Mangoceuticals, Common Stock over the last few years. It is Mangoceuticals, Common's Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

Mangoceuticals, Total Debt To Capitalization Regression Statistics

Arithmetic Mean1.42
Geometric Mean0.99
Coefficient Of Variation47.39
Mean Deviation0.52
Median1.74
Standard Deviation0.67
Sample Variance0.45
Range1.6693
R-Value(0.70)
Mean Square Error0.25
R-Squared0.49
Significance0
Slope(0.10)
Total Sum of Squares6.32

Mangoceuticals, Total Debt To Capitalization History

2024 0.0722
2023 0.076
2022 0.21

About Mangoceuticals, Common Financial Statements

Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.08  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.